213 related articles for article (PubMed ID: 34486922)
1. Etonogestrel-releasing contraceptive implant in a patient using thalidomide for the treatment of erythema nodosum leprosum: a case report.
Ferreira-Filho ES; Bahamondes L; Duarte DC; Guimarães ALM; de Almeida PG; Soares-Júnior JM; Baracat EC; Sorpreso ICE
Gynecol Endocrinol; 2022 Jan; 38(1):90-93. PubMed ID: 34486922
[TBL] [Abstract][Full Text] [Related]
2. Extended use up to 5 years of the etonogestrel-releasing subdermal contraceptive implant: comparison to levonorgestrel-releasing subdermal implant.
Ali M; Akin A; Bahamondes L; Brache V; Habib N; Landoulsi S; Hubacher D;
Hum Reprod; 2016 Nov; 31(11):2491-2498. PubMed ID: 27671673
[TBL] [Abstract][Full Text] [Related]
3. A 3-year multicentre randomized controlled trial of etonogestrel- and levonorgestrel-releasing contraceptive implants, with non-randomized matched copper-intrauterine device controls.
Bahamondes L; Brache V; Meirik O; Ali M; Habib N; Landoulsi S;
Hum Reprod; 2015 Nov; 30(11):2527-38. PubMed ID: 26409014
[TBL] [Abstract][Full Text] [Related]
4. Immediate versus delayed insertion of an etonogestrel releasing implant at medical abortion-a randomized controlled equivalence trial.
Hognert H; Kopp Kallner H; Cameron S; Nyrelli C; Jawad I; Heller R; Aronsson A; Lindh I; Benson L; Gemzell-Danielsson K
Hum Reprod; 2016 Nov; 31(11):2484-2490. PubMed ID: 27664217
[TBL] [Abstract][Full Text] [Related]
5. Dose-dependent thalidomide induced bradycardia in young erythema nodosum leprosum patient.
Thangaraju P; Venkatesan S; Sivashanmugam E; Showkath Ali MK
Indian J Pharmacol; 2019; 51(1):72-74. PubMed ID: 31031470
[TBL] [Abstract][Full Text] [Related]
6. ENG-releasing subdermal implants in postpartum teenagers - an open-label trial study protocol.
Barbieri MM; Juliato CRT; Bahamondes L; Surita FG
Reprod Health; 2020 Jun; 17(1):100. PubMed ID: 32576199
[TBL] [Abstract][Full Text] [Related]
7. [Thalidomide used by patients with erythema nodosum leprosum].
Valente Mdo S; Vieira JL
Rev Soc Bras Med Trop; 2010; 43(2):201-4. PubMed ID: 20464154
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and continuation rates of the etonogestrel-subdermal contraceptive implant versus short-acting contraceptive methods offered at no cost in Campinas, Brazil.
Laporte M; Marcelino AC; da Cunha Pereira P; Espejo-Arce X; Juliato CT; Bahamondes L
Int J Gynaecol Obstet; 2024 Jul; 166(1):305-311. PubMed ID: 38328989
[TBL] [Abstract][Full Text] [Related]
9. [Treatment of erythema nodosum leprosum using thalidomide].
Sheskin J
Acta Leprol; 1983; 1(1):41-50. PubMed ID: 6401140
[No Abstract] [Full Text] [Related]
10. Pilot study of a novel, alternative subdermal scapular insertion site for the etonogestrel contraceptive implant.
Clure C; Sheeder J; Lazorwitz A
Contraception; 2024 Jul; 135():110442. PubMed ID: 38552822
[TBL] [Abstract][Full Text] [Related]
11. Etanercept in erythema nodosum leprosum.
Santos JRS; Vendramini DL; Nery JADC; Avelleira JCR
An Bras Dermatol; 2017; 92(4):575-577. PubMed ID: 28954119
[TBL] [Abstract][Full Text] [Related]
12. Our experience of the use of thalidomide in the steroid-dependent severe erythema nodosum leprosum.
Chaudhry NS; Rath SR; Visvanath V; Torsekar RG
Indian J Dermatol Venereol Leprol; 2009; 75(2):189-90. PubMed ID: 19293514
[No Abstract] [Full Text] [Related]
13. A 12-month multicenter, randomized study comparing the levonorgestrel intrauterine system with the etonogestrel subdermal implant.
Apter D; Briggs P; Tuppurainen M; Grunert J; Lukkari-Lax E; Rybowski S; Gemzell-Danielsson K
Fertil Steril; 2016 Jul; 106(1):151-157.e5. PubMed ID: 27016644
[TBL] [Abstract][Full Text] [Related]
14. A multicenter randomized clinical trial of etonogestrel and levonorgestrel contraceptive implants with nonrandomized copper intrauterine device controls: effect on weight variations up to 3 years after placement.
Bahamondes L; Brache V; Ali M; Habib N;
Contraception; 2018 Sep; 98(3):181-187. PubMed ID: 29777663
[TBL] [Abstract][Full Text] [Related]
15. Thalidomide in erythema nodosum leprosum.
Jew LJ; Middleton RK
DICP; 1990 May; 24(5):482-3. PubMed ID: 2188435
[No Abstract] [Full Text] [Related]
16. Thalidomide in erythema nodosum leprosum (ENL).
Bourdillon C
Lepr Rev; 1988 Jun; 59(2):184-5. PubMed ID: 3246930
[No Abstract] [Full Text] [Related]
17. Thalidomide for erythema nodosum leprosum and other applications.
Okafor MC
Pharmacotherapy; 2003 Apr; 23(4):481-93. PubMed ID: 12680478
[TBL] [Abstract][Full Text] [Related]
18. Thalidomide's effectiveness in erythema nodosum leprosum is associated with a decrease in CD4+ cells in the peripheral blood.
Shannon EJ; Ejigu M; Haile-Mariam HS; Berhan TY; Tasesse G
Lepr Rev; 1992 Mar; 63(1):5-11. PubMed ID: 1569817
[TBL] [Abstract][Full Text] [Related]
19. Menstrual bleeding patterns in adolescents using etonogestrel (ENG) implant.
Deokar AM; Jackson W; Omar HA
Int J Adolesc Med Health; 2011; 23(1):75-7. PubMed ID: 21721368
[TBL] [Abstract][Full Text] [Related]
20. Bioequivalence and x-ray visibility of a radiopaque etonogestrel implant versus a non-radiopaque implant: a 3-year, randomized, double-blind study.
Schnabel P; Merki-Feld GS; Malvy A; Duijkers I; Mommers E; van den Heuvel MW
Clin Drug Investig; 2012 Jun; 32(6):413-22. PubMed ID: 22540269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
